Acute lymphoblastic leukaemia (ALL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051101

ALL restriction and item codes

Do not share these attachments externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS ALL blinatumomab/inotuzumab restriction and item codes

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS ALL imatinib/dasatinib/ponatinib restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Acute lymphoblastic leukaemia - blinatumomab initial (induction) authority application (PB210)

Acute lymphoblastic leukaemia - blinatumomab - initial grandfather authority application (PB381)

Acute lymphoblastic leukaemia - inotuzumab initial (induction) authority application (PB269)

Acute lymphoblastic leukaemia - first line - dasatinib - initial (induction and consolidation) PBS authority application (PB271)

Acute lymphoblastic leukaemia - second line - dasatinib - initial PBS authority application (PB077)

Acute lymphoblastic leukaemia - ponatinib - initial authority application form (PB169)

Services Australia website

Acute lymphoblastic leukaemia

External websites

PBS schedule for acute lymphoblastic leukaemia

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	When processing a blinatumomab initial request, what is the correct process to follow if the Q&As in OPA do not align with the application form? Check to ensure that the correct item and restriction code are selected as multiple indications are on the same application form.
2	What is the procedure when a prescriber calls requesting a dose reduction for inotuzumab ozogamicin? If the dose change is more than 10% (increase or decrease): a replacement script must be approved under the same item and restriction code as the previous approval. Answers to questions of the previous approval can be used to complete the Q&As, and override the rejection and add an authority comment 'dose change'.
3	What is the procedure when a prescriber or pharmacist calls stating that the quantity approved for inotuzumab ozogamicin is not sufficient to provide the 3 doses required for each cycle of treatment? Escalate to a Pharmaceutical Adviser (PA).
4	What is the procedure for handling a delayed assessment application when a prescriber uses the Online PBS Authorities (OPA) system to request dasatinib for first-line or second-line initial treatment, or for a switch during the first-line initial phase due to toxicity? Start by confirming that a relevant pathology report is attached and that it matches the correct patient. Once this is verified, escalate the application to a PA.
5	What is the procedure if an incorrect/unrelated report is uploaded for a delayed dasatinib application submitted via the OPA system? Reject the application if an incorrect or unrelated report (such as a random image) is attached. Authority requests for first-line or second-line initial treatment, or for a switch during the first-line initial phase due to toxicity, must include a valid pathology report. Escalate to a PA if unsure.